DataMeds AI, Inc. (NASDAQ:MDS): Strategic Rebranding, AI-Driven Growth, and New Trading Symbol
Key Highlights for Investors
- Corporate Name Change: Wellgistics Health, Inc. has officially changed its corporate name to DataMeds AI, Inc., reflecting a strategic pivot towards artificial intelligence (AI) integration in healthcare IT.
- New Trading Symbol: Shares will begin trading under the new symbol MDS on NASDAQ Capital Market starting Wednesday, July 22, 2026.
- Vertically Integrated Health Ecosystem: DataMeds aims to create a comprehensive, vertically aligned healthcare platform leveraging AI, blockchain, and data management technologies to empower patients, providers, and payors.
- Product Expansion: The company is expanding the functionalities of its AI-driven pharmacy dispensing platform, EinsteinRx™, and blockchain-enabled PharmacyChain™, targeting broader applications in medical, laboratory, and wearable device sectors.
- Patient-Centric Data Control: Through the Health Lives Here app, DataMeds plans to consolidate patient health data, enable patient participation in data transaction revenue, and facilitate tailored clinical trials for both prescription and nutraceutical products.
- Strategic Business Combination: The press release discloses a proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings, and HealthBridge Advisors, which may impact the company’s structure and capital base.
- Potential Rebranding: Plans include rebranding the pharmacy and pharmacy services division as Corexa Health.
Details and Strategic Vision
DataMeds AI, Inc. is repositioning itself at the forefront of digital health transformation. The company is integrating its proprietary AI platform EinsteinRx™ into its patented PharmacyChain™ smart contracts platform and expanding these capabilities to medical, laboratory, and wearable technology domains.
The Health Lives Here app, which is central to DataMeds’ patient engagement strategy, will initially focus on GLP-1-associated muscle loss and Long COVID patient segments. The app aims to aggregate electronic health data into a proprietary blockchain infrastructure, allowing patients not only to control and monetize their data but also to reduce friction for healthcare providers and enable precision clinical trial offerings.
According to Interim Co-CEO Gerald E. Commissiong, the rebranding marks a significant step towards empowering patients to take charge of their health data. The company envisions a digital health ecosystem that improves efficiency and care outcomes by breaking down data-sharing silos across stakeholders—patients, providers, pharmacists, manufacturers, and payors.
The company’s business model now spans telemedicine, pharmacy, laboratory, wearables, artificial intelligence, blockchain, and data management technologies. This expansion is expected to open new revenue streams, particularly through patient participation in data transactions and personalized healthcare solutions.
Key Information for Shareholders and Potential Price Sensitivities
- Corporate Actions: The official name change and new trading symbol are significant corporate events that can drive share trading activity.
- Expansion into AI and Blockchain: The company’s focus on integrating AI and blockchain for health data management and patient engagement could attract investor interest and strategic partnerships, enhancing long-term value.
- Pending Transactions: The disclosed negotiations and proposed business combinations with multiple partners could significantly impact the company’s structure, capitalization, and potential for growth. Completion of these transactions is subject to shareholder and regulatory approvals.
- Forward-Looking Risks: The company’s statements highlight several material risks, including the successful integration of new technologies and business units, regulatory and compliance hurdles, data privacy and monetization challenges, the ability to maintain NASDAQ listing standards, and the need for additional capital. Any adverse outcomes in these areas could affect share value.
- Forward-Looking Statements Disclaimer: The company notes that forward-looking statements are based on current expectations and subject to risks and uncertainties. Actual results may differ materially from those projected.
Contact Information
Media Contact:
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212-805-3024
Email: [email protected]
Investor Contact:
[email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements in the company’s press release are subject to risks and uncertainties, and actual outcomes may differ materially. Investors should perform their own due diligence and consult with a qualified financial advisor before making investment decisions.
